Literature DB >> 9792585

Intraoperative brachytherapy following thoracoscopic wedge resection of stage I lung cancer.

T A d'Amato1, M Galloway, G Szydlowski, A Chen, R J Landreneau.   

Abstract

STUDY
OBJECTIVES: Local recurrence is high when sublobar resection is chosen as primary management of stage I non-small cell lung carcinoma. Postoperative external-beam radiotherapy may reduce this local recurrence problem. A technique of intraoperative brachyradiotherapy following thoracoscopic wedge resection is described as an alternative to adjuvant external-beam radiotherapy for high-risk patients who are not candidates for pulmonary lobectomy. PATIENTS: Fourteen patients with significant impairment in cardiopulmonary function having small peripheral solitary pulmonary nodules underwent video-assisted thoracoscopic (VATS) wedge resection and were found to have non-small cell cancer. Surgical margins were pathologically clear and mediastinal nodes were benign-stage I (T1NO).
INTERVENTIONS: A custom polyglyconate mesh (Vicryl) containing 125I seeds was applied to pulmonary resection margins following wedge resection of peripheral lung cancers. A total dose of 100 to 120 Gy at 1 cm was applied to the target area.
RESULTS: All patients had histologically clear surgical margins. Postoperative dosimetry confirmed adequate resection margin coverage. There was neither operative mortality nor morbidity related to the VATS wedge resection or the brachytherapy implants. Implants did not migrate, and there were no cases of significant radiation pneumonitis or local recurrence at mean follow-up of 7 months (range, 2 to 12 months).
CONCLUSIONS: Intraoperative brachytherapy appears to be a safe and efficient alternative to external-beam radiation therapy when adjuvant radiotherapy is considered following therapeutic wedge resection of stage I (T1NO) lung cancers. The impact on local recurrence, disease-free interval, and survival will require additional follow-up.

Entities:  

Mesh:

Year:  1998        PMID: 9792585     DOI: 10.1378/chest.114.4.1112

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  14 in total

1.  A method for improved verification of entire IMRT plans by film dosimetry.

Authors:  Vesna Jacob; Peter Kneschaurek
Journal:  Strahlenther Onkol       Date:  2009-02-18       Impact factor: 3.621

2.  Impact of micropapillary histologic subtype in selecting limited resection vs lobectomy for lung adenocarcinoma of 2cm or smaller.

Authors:  Jun-ichi Nitadori; Adam J Bograd; Kyuichi Kadota; Camelia S Sima; Nabil P Rizk; Eduardo A Morales; Valerie W Rusch; William D Travis; Prasad S Adusumilli
Journal:  J Natl Cancer Inst       Date:  2013-08-07       Impact factor: 13.506

3.  Impact of brachytherapy on local recurrence rates after sublobar resection: results from ACOSOG Z4032 (Alliance), a phase III randomized trial for high-risk operable non-small-cell lung cancer.

Authors:  Hiran C Fernando; Rodney J Landreneau; Sumithra J Mandrekar; Francis C Nichols; Shauna L Hillman; Dwight E Heron; Bryan F Meyers; Thomas A DiPetrillo; David R Jones; Sandra L Starnes; Angelina D Tan; Benedict D T Daly; Joe B Putnam
Journal:  J Clin Oncol       Date:  2014-06-30       Impact factor: 44.544

4.  The impact of adjuvant brachytherapy with sublobar resection on pulmonary function and dyspnea in high-risk patients with operable disease: preliminary results from the American College of Surgeons Oncology Group Z4032 trial.

Authors:  Hiran C Fernando; Rodney J Landreneau; Sumithra J Mandrekar; Shauna L Hillman; Francis C Nichols; Bryan Meyers; Thomas A DiPetrillo; Dwight Heron; David R Jones; Benedict D T Daly; Sandra L Starnes; Jeffrey E Hatter; Joe B Putnam
Journal:  J Thorac Cardiovasc Surg       Date:  2011-07-02       Impact factor: 5.209

5.  Computed tomography fluoroscopy-guided percutaneous 125I seed implantation for safe, effective and real-time monitoring radiotherapy of inoperable stage T1-3N0M0 non-small-cell lung cancer.

Authors:  Jiakai Li; Miao Yu; Yueyong Xiao; Li Yang; Jinshan Zhang; Erik Ray; Xiaoming Yang
Journal:  Mol Clin Oncol       Date:  2013-08-23

Review 6.  Locoregional recurrence after pulmonary sublobar resection of non-small cell lung cancer: can it be reduced by considering cancer cells at the surgical margin?

Authors:  Noriyoshi Sawabata
Journal:  Gen Thorac Cardiovasc Surg       Date:  2012-09-29

Review 7.  Primary Treatment Options for High-Risk/Medically Inoperable Early Stage NSCLC Patients.

Authors:  Guy C Jones; Jason D Kehrer; Jenna Kahn; Bobby N Koneru; Ram Narayan; Tarita O Thomas; Kevin Camphausen; Minesh P Mehta; Aradhana Kaushal
Journal:  Clin Lung Cancer       Date:  2015-04-23       Impact factor: 4.785

8.  A novel ytterbium-169 brachytherapy source and delivery system for use in conjunction with minimally invasive wedge resection of early-stage lung cancer.

Authors:  Kara Lynne Leonard; Thomas A DiPetrillo; John J Munro; David E Wazer
Journal:  Brachytherapy       Date:  2010-08-12       Impact factor: 2.362

9.  Thirty- and ninety-day outcomes after sublobar resection with and without brachytherapy for non-small cell lung cancer: results from a multicenter phase III study.

Authors:  Hiran C Fernando; Rodney J Landreneau; Sumithra J Mandrekar; Shauna L Hillman; Francis C Nichols; Bryan Meyers; Thomas A DiPetrillo; Dwight E Heron; David R Jones; Benedict D T Daly; Sandra L Starnes; Angelina Tan; Joe B Putnam
Journal:  J Thorac Cardiovasc Surg       Date:  2011-08-26       Impact factor: 5.209

10.  Influenza infection induces host DNA damage and dynamic DNA damage responses during tissue regeneration.

Authors:  Na Li; Marcus Parrish; Tze Khee Chan; Lu Yin; Prashant Rai; Yamada Yoshiyuki; Nona Abolhassani; Kong Bing Tan; Orsolya Kiraly; Vincent T K Chow; Bevin P Engelward
Journal:  Cell Mol Life Sci       Date:  2015-03-26       Impact factor: 9.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.